CSC
GMAB icon

Caldwell Sutter Capital’s Genmab GMAB Stock Holding History

Caldwell Sutter Capital’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-22
Closed -$700 – 946
2023
Q4 		$700 Hold
22
– – ﹤0.01% 862
2023
Q3 		$776 Hold
22
– – ﹤0.01% 810
2023
Q2 		$836 Hold
22
– – ﹤0.01% 806
2023
Q1 		$831 Buy
+22
New +$846 ﹤0.01% 536

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caldwell Sutter Capital's GMAB Position: Q1 2024 in Review

Caldwell Sutter Capital sold out of Genmab (GMAB) in Q1 2024, closing a stake of 22 shares — an estimated $700 sold.

Caldwell Sutter Capital first reported a position in GMAB in Q1 2023 and held it in 4 quarters. The position peaked at $836 in Q2 2023. 227 funds tracked by Wall St. Rank hold GMAB as of Q1 2024.

  • Caldwell Sutter Capital reported no remaining Genmab position as of Q1 2024 after selling out during the quarter.
  • Caldwell Sutter Capital sold 22 Genmab shares in Q1 2024, an estimated $700.
  • Caldwell Sutter Capital first reported a position in Genmab in Q1 2023 and held it in 4 quarters.
  • Caldwell Sutter Capital's Genmab position peaked at $836 in Q2 2023.
  • 227 funds tracked by Wall St. Rank held Genmab as of Q1 2024.

Based on Caldwell Sutter Capital's 13F filing for Q1 2024, filed 19 Apr 2024.